Estrella Immunopharma, Inc.
ESLA
$0.7936
-$0.0428-5.12%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -80.52% | -44.65% | 82.87% | 62.97% | 35.17% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -100.00% | -100.00% | -100.00% | 1,066.70% |
| Change in Net Operating Assets | 189.32% | 40.74% | -247.72% | -503.91% | -76.19% |
| Cash from Operations | -705.78% | -574.77% | -4,911.36% | -10,313.12% | 74.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | 100.00% | -- | -- |
| Cash from Investing | -- | 100.00% | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.75% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.04% | -212.51% | -1,854.16% | -11,999.82% | 1,886.84% |